Idris Muhammad, Farid Jamila, Sarwar Javed, Ahmed Suhaib, Wiqar Muhammad Amin, Badsha Shahida
Department of Pathology, Ayub Medical College, Abbottabad, Pakistan.
J Ayub Med Coll Abbottabad. 2010 Jul-Sep;22(3):8-11.
Acute lymphoblastic leukaemia (ALL), a malignancy of lymphoid lineage cells, has excellent prognosis in children. In Pakistan, a few studies highlighted the response of ALL to chemotherapy. The Present study was planned to see the response rate of Pakistani children with ALL to Medical Research Council ALL 97 (MRCALL97) chemotherapy protocol. This descriptive case series was conducted at the Department of Haematology, Armed Forces Institute of Pathology and the Department of Paediatric Oncology, Combined Military Hospital, Rawalpindi from 16th of February 2007 to 16th of August 2007.
Diagnosed children with ALL fulfilling the inclusion criteria were interviewed regarding history of the present, past illnesses, and family history. Physical examination was performed. Presenting clinical features, blood counts and blood and bone marrow blasts percentage were used to see the response on day 29 post chemotherapy. The data was recorded on a structured proforma for statistical analysis.
A total of 33 patients were studied including 26 males and 7 females. Twenty-five patients belonged to age group 2-9 years, and 8 to < 2 or > 9 years, median age being 4.5 years. Presenting WBC count was < 50 x 10(9)/L in 30 patients and > 50 x 10(9)/L in 3 patients. At the end of induction, complete remission was achieved in 31 out of 33 (94%) patients while two patients did not achieve remission.
Response rate of Pakistani children with ALL to chemotherapy was superior to the previously reported figures from Pakistan.
急性淋巴细胞白血病(ALL)是一种淋巴系细胞恶性肿瘤,在儿童中预后良好。在巴基斯坦,有几项研究强调了ALL对化疗的反应。本研究旨在观察巴基斯坦ALL患儿对医学研究委员会ALL 97(MRC ALL97)化疗方案的反应率。本描述性病例系列研究于2007年2月16日至2007年8月16日在拉瓦尔品第武装部队病理研究所血液科和联合军事医院儿科肿瘤科进行。
对符合纳入标准的确诊ALL患儿进行了关于现病史、既往疾病史和家族史的访谈。进行了体格检查。使用化疗后第29天的临床表现、血细胞计数以及血液和骨髓原始细胞百分比来观察反应情况。数据记录在结构化表格上用于统计分析。
共研究了33例患者,其中男性26例,女性7例。25例患者年龄在2至9岁之间,8例年龄小于2岁或大于9岁,中位年龄为4.5岁。30例患者的初诊白细胞计数<50×10⁹/L,3例患者>50×10⁹/L。诱导结束时,33例患者中有31例(94%)达到完全缓解,2例未达到缓解。
巴基斯坦ALL患儿对化疗的反应率优于巴基斯坦先前报道的数据。